Horizons Psychedelic Stock Index ETF(PSYK-NE)Cboe CA
Today's Change
Real-Time Last Update
After Hours Change
After Hours Last Update
Volume
Latest News
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
Globe NewsWire - Tue Sep 21, 2021
Globe NewsWire
Tue Sep 21, 2021
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Company has been included to the...
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
Globe NewsWire - Tue Sep 7, 2021
Globe NewsWire
Tue Sep 7, 2021
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce...
Optimi Health Appoints New Chief Executive Officer
Globe NewsWire - Tue Aug 31, 2021
Globe NewsWire
Tue Aug 31, 2021
VANCOUVER, British Columbia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), developers of a vertically integrated functional mushroom brand focused on the health and...
Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant
Globe NewsWire - Wed Aug 11, 2021
Globe NewsWire
Wed Aug 11, 2021
VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce...
Optimi Health Updates Launch of Online Functional Mushroom Sales
Globe NewsWire - Tue Aug 10, 2021
Globe NewsWire
Tue Aug 10, 2021
VANCOUVER, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and...
Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College
Globe NewsWire - Mon Aug 9, 2021
Globe NewsWire
Mon Aug 9, 2021
VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce...
Optimi Health Strengthens Clinical and Regulatory Expertise
Globe NewsWire - Tue Jul 27, 2021
Globe NewsWire
Tue Jul 27, 2021
VANCOUVER, British Columbia, July 27, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate the science of mushrooms, is pleased to...
Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
Globe NewsWire - Wed Jul 7, 2021
Globe NewsWire
Wed Jul 7, 2021
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, announces that it has...
Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19
Globe NewsWire - Tue Jul 6, 2021
Globe NewsWire
Tue Jul 6, 2021
VANCOUVER, British Columbia, July 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it will not...
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
Globe NewsWire - Thu Jun 17, 2021
Globe NewsWire
Thu Jun 17, 2021
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all of the required permits and licenses for the...
Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil
Globe NewsWire - Thu Jun 3, 2021
Globe NewsWire
Thu Jun 3, 2021
VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a new clinical research program for pancreatic...
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
Globe NewsWire - Thu May 27, 2021
Globe NewsWire
Thu May 27, 2021
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an independent research study from the University of...
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
Globe NewsWire - Mon May 17, 2021
Globe NewsWire
Mon May 17, 2021
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received positive feedback from the U.S. Food and Drug...
Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study
Globe NewsWire - Wed May 12, 2021
Globe NewsWire
Wed May 12, 2021
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company announces that NP-120...
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
Globe NewsWire - Tue May 11, 2021
Globe NewsWire
Tue May 11, 2021
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company is pleased to announce...
Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil
Globe NewsWire - Mon Apr 26, 2021
Globe NewsWire
Mon Apr 26, 2021
VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it has...
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
Globe NewsWire - Thu Apr 8, 2021
Globe NewsWire
Thu Apr 8, 2021
VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce...
Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program
Globe NewsWire - Tue Apr 6, 2021
Globe NewsWire
Tue Apr 6, 2021
VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce...
Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil
Globe NewsWire - Wed Mar 31, 2021
Globe NewsWire
Wed Mar 31, 2021
VANCOUVER, British Columbia, March 31, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce...
Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
Globe NewsWire - Mon Mar 29, 2021
Globe NewsWire
Mon Mar 29, 2021
VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce...
Greenbrook TMS Included in First Psychedlics-Focused Exchange Traded Fund
Business Wire - Wed Jan 27, 2021
Business Wire
Wed Jan 27, 2021
Greenbrook TMS Inc. (TSX:GTMS) (“ Greenbrook ” or the “ Company ”) is pleased to announce that it is one of seventeen companies in the U.S. and Canada that will be included in the world’s first psychedelics focused exchange traded fund, which is...
Horizons ETFs Launches World’s First-Ever Psychedelic ETF on NEO Exchange
Business Wire - Wed Jan 27, 2021
Business Wire
Wed Jan 27, 2021
With much excitement, NEO proudly welcomes Horizons ETFs Management (Canada) Inc. (“Horizons ETFs”) back to the NEO Exchange, with the launch of the world’s first-ever psychedelics-focused exchange traded fund. The Horizons Psychedelic Stock...